You are here : Home » Lakeland Regional Cancer Center » Research and Clinical Trials » Leukemia
Clinical Trial #E2903:
-
Standard chemotherapy followed by Campath-1H for patients previously treated for CLL (Chronic Lymphocytic Leukemia) who have recurrent disease.
-
Participants must be B-CLL. Prior Rituximab is allowed as long as it was at least 8 weeks prior to start of the trial. Patients with Gilbert’s Syndrome are eligible. Patients must require chemotherapy with the last infusion scheduled at least 6 weeks out from the start of the trial.
-
Exclusions include, but are not limited to: Active infections, HIV, grade II or IV heart problems, another cancer unless cured at least 2 years ago and previous PCR or Campath 1-H treatments.
